"Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies"
Microdosing GLP-1/GIP therapies may help: Improve glycemic control, stable blood glucose levels, and blood pressure support Reduction in visceral fat and waist circumference Potential improvements in lipid profiles Reduce systemic inflammation markers associated with cardiometabolic disease Glycine amino acid that supports protein synthesis, endothelial function, and insulin sensitivity Reduce cardiovascular risk factors such as insulin resistance and central adiposity Whats Included Monthly compounded tirzepatide + glycine (Up to 3mg/week) or 2ml tirzepatide with B12 every 2 months with labs Personalized microdosing protocol Ongoing provider oversight with labs every six months This is not an FDA-approved microdosing regimen
Its best to discuss your alcohol consumption with your provider to understand any potential risks to your metabolic health
This reduction in inflammation may explain some of the improvements in joint pain and energy that users report during the early months of treatment
Above all, view every spin or hand as paid entertainment rather than an income plan
Type 2 diabetes patients taking GLP-1 drugs were overall less likely to die within the next year, but those with sleep apnea did even better, researchers reported Monday at a meeting of the American College of Chest Physicians in Chicago
